Cuộc họp công bố kết quả kinh doanh Q3 2026 của DaVita (DVA): Triển vọng IKC tăng, thu hẹp khoảng dự báo
Lợi nhuận hoạt động đã điều chỉnh Quý 3/2026 của DaVita đạt 561 triệu USD khi dự báo IKC tăng và dự báo EPS cả năm thu hẹp xuống khoảng 14,30 - 15,20 USD.
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.